Literature DB >> 1977483

Nephrotic syndrome associated with sulphasalazine.

V M Barbour1, P F Williams.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1977483      PMCID： PMC1663947          DOI： 10.1136/bmj.301.6755.818-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Nephrotic syndrome after treatment with 5-aminosalicylic acid.

Authors:  B H Novis; Z Korzets; P Chen; J Bernheim
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

Review 2.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447
  3 in total
  13 in total

1.  A prospective study of renal disease in patients with early rheumatoid arthritis.

Authors:  Y Koseki; C Terai; M Moriguchi; M Uesato; N Kamatani
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

2.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

3.  Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss.

Authors:  E A Masson; J M Rhodes
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

Review 4.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

5.  Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.

Authors:  Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

Review 6.  Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?

Authors:  A A van Bodegraven; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Sulphasalazine induced renal failure.

Authors:  A D Dwarakanath; J Michael; R N Allan
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

8.  Mesalazine induced interstitial nephritis.

Authors:  P J Thuluvath; M Ninkovic; J Calam; M Anderson
Journal:  Gut       Date:  1994-10       Impact factor: 23.059

9.  Tests of renal function in patients with quiescent colitis: effects of drug treatment.

Authors:  S A Riley; D R Lloyd; V Mani
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

10.  No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases.

Authors:  Carsten Dehmer; Roland Greinwald; Juergen Löffler; Wolfgang Grotz; Lothar Wolf; Hans-Burkhardt Hagmann; Werner Schneider; Wolfgang Kreisel
Journal:  Int J Colorectal Dis       Date:  2003-02-08       Impact factor: 2.571
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.